'Bausch Health’s stock gains on improved outlook Bausch Health Companies Inc. (NYSE: BHC) missed revenue expectations for the first quarter of 2019 and did not provide a number for adjusted EPS. The company raised its full-year 2019 guidance, allowing shares to gain 2.6% in premarket hours on Monday. Total revenues of $2.01 billion were up 1% compared to the same period last year. Organic sales growth was 5%. GAAP net loss was $52 million, or $0.15 per share, compared to $2.5 billion, or $7.36 per share, in the year-ago quarter. Adjusted net income increased 15% to $358 million. Revenues in the Bausch + Lomb/International segment increased 1% year-over-year to $1.11 billion while revenues in the Salix segment grew 5% to $445 million. Earnings Calendar: https://alphastreet.com/symbol/BHC/earnings-calendar Earnings Calls: https://alphastreet.com/symbol/BHC/earnings-calls Earnings Transcripts: https://alphastreet.com/symbol/BHC/earnings-call-transcripts SEC Filings: https://alphastreet.com/symbol/BHC/sec-filings'
Tags: stock market , Investing , Bausch Health , Bausch Health earnings call , BHC stock price , BHC earnings call , Bausch Health stock price , Bausch Health quarterly report , earnings conference calls , healthcare company , pharmaceutical company , Valeant Pharmaceutical , pharma stock , healthcare stocks , quarterly report
See also:
comments